Latest News

We wanted to highlight on our recent article on our psychopharmacology research "The Anxiolytic-like Properties of a Tryptic Hydrolysate of Bovine αs1 Casein Containing α-Casozepine Rely on GABAA Receptor Benzodiazepine Binding Sites but Not the Vagus Nerve" that has reached over 3000 views in MDPI Nutrients journal!   The published data on the anxiolytic-like properties of bovine αs1-casein (CH) support that: α-casozepine is responsive for the anxiolytic-like effects of the alpha-s1-casein tryptic hydrolysate (CH). CH anxiolytic-like effects are not mediated by the

🎥 Today we're sharing a documentary about Parkinson's on the famous French program "Health Investigation: Our Lives with Parkinson's" Parkinson's disease is the second leading cause of motor disability in adults after strokes, with 25,000 new cases each year in France. To date, there is no cure for this complex disorder, so research continues !   🧠 In this documentary, journalist and producer Joseph Coriat, diagnosed at 38, shares his experience and meets with 6 persons to talk about daily life with

📌ETAP-Lab is delighted to present for the first time a poster at the American Heart Association’s annual International Stroke Conference 2025, in Los Angeles, CA from February 5 to 7, 2025. As a leading international conference in cerebrovascular disease and brain health, the AHA's International Stroke Conference was the ideal platform to highlight our preclinical stroke research expertise.   ETAP-Lab, preclinical efficacy CRO, will be presenting its poster on original preclinical results about in vivo trials on Stroke disease.   📅Meet our expert during the

Our mission is to contribute to the development of molecules and therapies for our customers in the field of human health. But that doesn't stop us from being amazed by the beauty of biology.   When art and biology meet, it results in #FluorescenceFriday!   We regularly share our most beautiful images, and love to look curiously at the publications of other passionate scientists. Join us by following the hashtag #FluorescenceFriday on LinkedIn if you're eager to be amazed, to have glitter in your eyes while

As we look back over the past year and forward to the future, we are grateful to our valued customers and partners, and the trust they place in us is our greatest gift. 🎁 But without our employees, nothing would be possible. That's why we thank everyone at ETAP-Lab, STROK@lliance and SYNCROSOME. We appreciate their dedication, passion and positive attitude on every day. With our teams growing, we're convinced that this new year will be a great one ! We look forward to

To prepare for tomorrow's industrial champions in healthcare, France is investing in its promising companies! We have been selected to join the Healthcare Industries and Technologies Accelerator, a selective, targeted and personalized program operated by Bpifrance as part of France 2030 to support innovative companies with high growth potential.   This program - financed by the French Ministry of the Economy, Finance and Industrial and Digital Sovereignty - will support the growth of 12 innovative French companies in the healthcare sector. They

We are delighted to announce the renewal of ETAP-Lab's ISO 9001 certification. This achievement underlines our commitment to providing exemplary preclinical research services.   A commitment to quality and customer satisfaction   Our robust quality management system, backed by our ISO9001 certification, ensures to our customers: compliance with rigorous quality standards: we follow established protocols and guidelines to ensure the accuracy and reliability of our services. Continuous improvement: We constantly focus on improving our processes and services, driven by a commitment to excellence. Customer-focused

🌍ETAP-Lab is happy to present a poster at the 16th World Stroke Congress (WSC 2024) in Abu Dhabi, UAE, from October 23-26, 2024 organized by the World Stroke Organization.   ETAP-Lab's team is looking forward to attending this global event that explores "the forefront of stroke and cerebrovascular disease topics and present the most influential late breaking clinical trials". As a preclinical efficacy CRO, ETAP-Lab will unveil its poster on original preclinical results about in vivo assays on Stroke disease. The results presented

Better than any certification, at ETAP-Lab we believe that customer recognition is the ultimate goal. We're proud to announce our strategic partnership with Kisolite Corp, a leader in innovative therapeutic solutions. Together, we're advancing in vivo studies for their treatment targeting Inflammatory Bowel Disease (IBD). Our dedication to building lasting relationships goes beyond expertise. Our flexible and human-sized organization offers personalized support, ensuring clients feel empowered throughout the research process.   Ready to collaborate on your next drug efficacy study? Contact us today

📌ETAP-Lab's team will attend the upcoming NEUROSCIENCE 2024 from Saturday, October 5 to Wednesday, October 9, in Chicago (IL, USA), in McCormick Place Convention Center. That meeting is the World's Largest Neuroscience Conference, organized by the Society For Neuroscience (SFN), and with an exciting programming for the scientists coming from around the world!   ETAP-Lab will unveil two posters on original preclinical results about in vitro and in vivo assays on Alzheimer's disease.   📅Let's meet our scientists during the poster sessions   Nicolas Violle, CEO